statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Trade Spotlight: How should you trade Bata, Divis Labs, Escorts, Mazagon Dock, HUDCO, Biocon, and others on Thursday?

Experts expect the Nifty 50 index to take support at the 22,600-22,500 zone, and above these levels, there is a possibility of a resumption of the upmove towards the 23,000 mark. However, below 22,500, a sharp downward move can't be ruled out.

Hold Divi's Laboratories; target of Rs 4478: KR Choksey

KR Choksey recommended hold rating on Divi's Laboratories with a target price of Rs 4478 in its research report dated May 28, 2024.

Divi's Labs' better-than-expected Q4 results trigger slew of price target upgrades

Despite brokerages raising price targets for Divi's Labs following its robust performance in Q4, they maintained neutral recommendations on the stock. Their rationale lies in the belief that the current stock valuations already the current stock valuations factor in much of its growth prospects.

Stock Radar: Aurobindo, Adani Ports, RVNL, NTPC, Torrent Pharma, Divis Labs, Glenmark in focus on Monday

More than 300 companies will release their quarterly earnings on May 27 including Life Insurance Corporation of India, Astrazeneca Pharma, Borosil Renewables, Flair Writing Industries, Jubilant Industries, Natco Pharma, and NALCO.

Divi’s Labs Q4 results: net profit up 67% to Rs 538 crore, Rs 30 dividend declared

Revenue for the quarter grew 18 percent from last year to Rs 2,303 crore. It was Rs 1,951 crore in the same period a year ago.

Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix

The pharma company is expected to deliver decent earnings in Q4 FY24 aided by strong growth across its generics, nutraceuticals and custom synthesis businesses.

Trade Spotlight: How should you trade Infosys, Coal India, Cipla, Divis Labs and others?

Despite elevated volatility, the market is expected to maintain an upward journey in the coming sessions, along with intermittent consolidation.

BoFA sees favourable risk reward in Divi's Labs, upgrades stock to 'buy'

BoFA also says the end of destocking cycle and peer commentary suggest bottoming out of margins in the near term for Divi's

Accumulate Divi’s Laboratories; target of Rs 3931: KR Choksey

KR Choksey recommended accumulate rating on Divi’s Laboratories with a target price of Rs 3931 in its research report dated April 03, 2024.

Divi's Lab Q3 results: Net profit up 17% to Rs 358 crore

The company reported a profit of Rs 306 crore in the same period last year.

Divi's Laboratories Ltd. is a holding company, which engages in the manufacture of active pharmaceutical ingredients, intermediates, and nutraceutical. It also provides manufacturing of generic APIs, nutraceutical ingredients, and custom synthesis for big pharma. The company was founded by Murali Krishna Prasad Divi on October 12, 1990 and is headquartered in Hyderabad, India.

Volume	1.26M
52-Wk High	4,670.00
52-Wk Low	3,295.30

DIVISLAB.NSE Divi`s Laboratories Ltd.

About

Feed

News

Sentiment

Fundamentals